Consulting assignments

    The Wilkerson Group (IBM Healthcare Consulting): Associate Consultant 1998-2000, Consultant 2000-2002), Project Leader (Senior Consultant on Projects #20 and #21). 1998-2002: Prof.Dr.Dr.Dr. F.G. Draenert underwent the consulting training of The Wilkerson Group Consulting (TWG) starting in early 1998 under Dr. Prosche (Principal; now Director) and Dr. Waterloh (Senior Consultant; now left for investment banking). The company is specialized in healthcare consulting and well-known in business. TWG was founded by John Wilkerson a New York based business man also running Galen investment company. TWG was acquired by IBM in 1997 and initially managed without changes to build relationships to the life science industry as IBM Healthcare Consulting. The company lost the initial human resources subsequently. One well-known successor is Easton Associates Inc., New York. (see attached list for details).

    Value Management: Pre-Marketing pricing strategy for a pharma player concerning a new cardiology drug. Service Impact Modelling. Analysis of the German Health Care system concerning payer, provider, and pharmacological key players. Mapping of the treatment paradigm and patient flow in cardiology leading to the development of a market strategy for a new therapeutic

    Value Management: Due dilligence for a major venture capitalist covering technical and financial aspects on a starter biotechnology company providing the basis for the investment decission in medical device implants for orthopaedics and dentistry

    Strategy: Environmental analysis and trends in pharmaceutical chemicals production on a global basis for the chemical production strategy of a major pharmaceutical player

    Strategy: Research and development strategy for a starter biotechnology company in drug delivery concerning the whole world of protein drugs including NBEs covering technical and financial aspects

    Strategy: Research and development strategy for a starter biotechnology company in drug delivery concerning the whole world of chemical drugs including NCEs covering technical and financial aspects

    Value Management: Market analysis of the medical device market for a major venture capital company covering market segments, product categories and leading companies for an investment strategy

    Value Management: Due dilligence for a major pharmaceutical player concerning an acquisition opportunity in oncology covering technical and financial aspects of a cancer franchise

    Value Management: Due dilligence for a major pharmaceutical player concerning an acquisition opportunity in hematology and oncology covering technical and financial aspects of a medical device

    Value Management: Due dilligence for a major venture capital company concerning an acquisition opportunity in herbal medicine covering technical and financial aspects of a cancer franchise

    Strategy: Research and development strategy for a medical device company concerning new opportunities including technology transfer for the main proprietary technology covering technical and financial aspects in drug delivery technologies

    Value Management: Due dilligence for a biotechnology company concerning a strategic opportunity in anti-inflammatory dermatologic therapy covering technical and financial aspects

    E-business: Strategy for an e-marketplace for a major pharmaceutical player in OTC business

    Value Management: Due dilligence and expert report for a major investment bank according to chapter 20 of London stock exchange rules for a public offering of a medical device player

    Value Management: Due dilligence for a medical device player concerning an acquisiton opportunity in critical care covering technical and financial aspects including NPV, EBITDA and capitalisation based valuation of a company

    Strategy: Acquisition Strategy for an engineering player concerning the creation of a healthcare franchise by acquisition covering technical and financial aspects

    Strategy: Acquisition Strategy for an engineering player concerning the screening and analysis of acquisition targets covering technical and financial aspects

    Strategy: Research and development strategy reevaluation for a leading biotechnology company concerning the whole R&D plan in antibody technologies covering clinical and technological aspects

    Value Management: Due dilligence for a major venture capitalist covering technical and financial aspects on a starter biotechnology company providing the basis for the investment decission in molecular biology technologies in infection diseases

    Value Management: Due dilligence for a major venture capitalist covering technical and financial aspects on a medical device company in radiodiagnostics and radiotherapy providing the basis for a second round investment decission

    Strategy: Acquisition Strategy for a phamaceutical player concerning the screening and analysis of acquisition targets covering technical and financial aspects

    Strategy: Business Reengineering for a major phamaceutical player concerning the restructuring of the whole marketing and sales structures in oncology

    Strategy: Acquisition Strategy for an engineering player concerning the screening and analysis of acquisition targets covering technical and financial aspects

    Strategy: Research and development strategy re-evaluation for a leading biotechnology company concerning the main R&D plan in neurodegenerative diseases covering clinical and technological aspects

    Strategy: Research and development strategy re-evaluation for a leading biotechnology company concerning the main R&D plan in cardiology covering clinical and technological aspects